Additionally, emerging CAR T-cell therapies are being designed to overcome metabolic challenges in solid tumors by enhancing mitochondrial function and resistance to tumor microenvironment stressors (48), which aligns with the metabolic pathways linked to PDCD4 observed in our analysis. The gene discussed is PDCD4; the disease is neoplasm.